Time to reframe the disease staging system for type 1 diabetes

Overview of attention for article published in The Lancet Diabetes & Endocrinology, December 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

twitter: 54 X users

bluesky: 5 Bluesky users

Readers on

mendeley: 34 Mendeley

So far, Altmetric has seen 7 Bluesky posts from 5 Bluesky users, with an upper bound of 2,345 followers.

"We call for the use of existing and new measures to improve type 1 #diabetes risk assessment and provide a more specific risk classification system for type 1 diabetes" thelancet.com/journals/lan... #T1D #staging #MedSky #EndoSky

With the approval of teplizumab by the US Food and Drug Administration in 2022 to delay type 1 #diabetes in people at stage 2, there is a need to refine the definition and accuracy of type 1 diabetes #staging www.thelancet.com/journals/lan... #T1D #Me…

Time to reframe the disease staging system for type 1 #diabetes thelancet.com/journals/lan... #T1D

RP @apoorvsuresh.bsky.social: "Quantification of disease progression risk is needed for an individual to make medical decisions (e.g. to enter a clinical trial or receive an approved therapeutic intervention)." www.thelancet.com/journals/lan... #diabe…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 3 additional Bluesky posts.